期刊文献+

瑞舒伐他汀钙对血脂正常的短暂性脑缺血发作患者血脂水平的影响 被引量:23

下载PDF
导出
摘要 目的观察瑞舒伐他汀钙对血脂正常的短暂性脑缺血发作患者血脂水平的影响。方法将68例血脂正常的短暂性脑缺血发作患者随机分为治疗组(34例)和对照组(34例)进行对比观察,对照组仅作神经内科常规治疗。治疗组除神经内科常规治疗,加服瑞舒伐他汀钙。检测治疗前后血脂水平,彩色超声检查治疗前后颈动脉内膜中层厚度,比较6个月内两组患者脑血管事件发生率。结果治疗组脑血管事件发生率(11.6%)低于对照组(29.8%,P<0.05)。治疗前两组血脂水平无差异(P>0.05),治疗后治疗组血清总胆固醇(TC),甘油三酯(TG),低密度脂蛋白胆固醇(LDL-C)较治疗前明显降低,高密度脂蛋白(HDL-C)显著升高(P<0.05)。3个月与6个月血脂无显著差异,而对照组治疗前后血脂无显著变化(P>0.05)。治疗前两组颈动脉内膜中层厚度差异无统计学意义,治疗组治疗前后颈动脉内膜厚度减少有显著差异,对照组治疗前后颈动脉内膜厚度减少无显著差异。结论瑞舒伐他汀钙不仅有调控血脂水平的作用,而且有明显的抗炎、抗动脉粥样硬化作用,对短暂性脑缺血发作的二期预防有显著效果,可明显降低缺血性卒中发生率。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2015年第5期1261-1262,共2页 Chinese Journal of Gerontology
  • 相关文献

参考文献4

  • 1Rifai N,Ridker PM.High-sensitivity C-reactive protein:a novel and promising marker of coronary heart disease. Clinical Chemistry . 2001
  • 2Vaughan C J.Prevention of stroke and dementia with statins: effects beyond lipid lowering. The American Journal of Cardiology . 2003
  • 3PRC-USA Cardiovascular and Cardiopulmonary Epidemiology Research Group.An epidemiological study of cardiopulmonary disease risk factors in the People’’s Republic of China.Base line report from the P.R.CU.S.A Collaborative Study. Circulation . 1992
  • 4王传锋,贾明兰.他汀类药物防治动脉粥样硬化的应用[J].中国现代医生,2008,46(10):29-30. 被引量:13

二级参考文献15

  • 1[1]Raymond CB,Morgan SG,Katz A,et al.A population-based analysis of statin utilization in British Columbia[J].Clin Ther,2007,29(9):2107-2119.
  • 2[2]O' Brien KD.Inflammatory proteins on HDL:what are we measuring[J].Transl Res,2007,150(3):150-152.
  • 3[3]Tziomalos K,Athyros VG,Karagiannis A,et al.Endothelial function,arterial stiffness and lipid lowering drugs[J].Expert Opin Ther Targets,2007,11 (9):1143-1160.
  • 4[4]Hjelstuen A,Anderssen SA,Holme I,et al.Effect of lifestyle and/or statin treatment on soluble markers of atherosclerosis in hypertensives[J].Scand Cardiovasc J,2007,41(5):313-320.
  • 5[5]Virani SS,Nambi V.The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis[J].Curt Atheroscler Rep,2007,9(2):97-103.
  • 6[6]Santiili F,Bucciarelli L,Noto D,et al.Decreased plasma soluble RAGE in patients with hypercholesterolemia:effects of statins[J].Free Radie Biol Med,2007,43(9):1255-1262.
  • 7[7]Vogt A,Kassner U,Hostalek U,et al.Correction of low HDL cholesterol to reduce cardiovascular risk:practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan)[J].Int J Chn Pract,2007,61(11):1914-1921.
  • 8[8]Smilde TJ,van Wissen S,Wollersheim H,et al.Efect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP):a prospective,randomized,double-blind trial[J].Lancet,2001,357(9256):577-581.
  • 9[9]Rizzo M,Bemeis K.Who needs to care about small,dense low-density lipoproteins[J].Int J Clin Pract,2007,61(11):1949-1956.
  • 10[10]Ali F,Hamdulay SS,Kinderlerer AR,et al.Statin-mediated cytoprotection of human vascular endothelial ceils:a role for Kruppel-like factor 2-dependent induction of heme oxygenase-I[J].J Thromb Haemost,2007,5 (12):2537-2546.

共引文献12

同被引文献98

引证文献23

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部